A Study of a Candidate COVID-19 Vaccine (COV003)

A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine

A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine.

Study Overview

• Status: Unknown
• Conditions: Coronavirus
• Intervention / Treatment: Biological: ChAdOx1 nCoV-19 single dose + paracetamol; Biological: MenACWY single dose + paracetamol; Biological: ChAdOx1 nCoV-19 two dose + paracetamol; Biological: MenACWY prime & saline placebo boost + paracetamol

Detailed Description

There will be 2 study groups and an anticipated enrolment of 10,300 health professionals and adults with high potential for exposure to SARS-CoV-2, aged ≥18 years.

All subjects will undergo follow-up for a total of 1 year post last vaccination. Additional visits or procedures may be performed at the discretion of the investigators, e.g., further medical history and physical examination, or additional blood tests and other investigations if clinically relevant

• Study Type: Interventional
• Enrollment (Anticipated): 10300
• Phase: Phase 3

Contacts and Locations

Study Locations

• Brazil
  • Rio de Janeiro, Brazil, 22281-100
    • Recruiting
    • Instituto D'Or de Pesquisa e Ensino - I'Dor
    • Principal Investigator: Ana Maria Pitella de Souze Leite
  • São Paulo, Brazil, 04038-001
    • Recruiting
    • CRIE, Universidade Federal de São Paulo
    • Principal Investigator: Lily Weckx
  • Bahia
    • Salvador, Bahia, Brazil, 41253-190
      • Recruiting
      • Instituto D'Or de Pesquisa e Ensino - I'Dor
      • Principal Investigator: Ana Verena Mendes
  • Rio Grande Do Norte
    • Natal, Rio Grande Do Norte, Brazil, 59025-050
      • Recruiting
      • Centro de Pesquisas Clinicas de Natal (CPCLIN)
      • Principal Investigator: Eveline Pipolo Milan
  • Rio Grande Do Sul
    • Porto Alegre, Rio Grande Do Sul, Brazil, 90035-903
      • Recruiting
      • Hospital das Clinicas de Porto Alegre
    • Santa Maria, Rio Grande Do Sul, Brazil, 97105-900
      • Recruiting
      • Universidade Federal de Santa Maria (UFSM)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Adults from 18 to 55 years of age
• Adults aged 56-69 years old (after review of safety data by DSMB in this age group in the UK trial)
• Adults aged 70 and above years old (after review of safety data by DSMB in this age group in the UK trial)
• Able and willing (in the Investigator's opinion) to fulfill all study requirements;
• Health professionals and adults at high risk of exposure to SARS-CoV-2, as defined in section 5.2 of this protocol;
• Serology with SARS-CoV-2 negative IgG antibodies; This inclusion criteria does not apply to participants enrolled from version 4.0 of the protocol onwards.
• Willing to allow investigators to discuss the participant's clinical history with their GP/personal physician and access medical records relevant to the study procedures
• Only for women of childbearing age willing to practice continuous effective birth control (see below) during the study, and a negative pregnancy test on the screening and vaccination day(s);
• Consent to abstain from blood donation during the course of the study;
• Provide informed consent in writing

Exclusion Criteria:

• Participation in trials of prophylactic drugs for COVID-19 during the course of the study; Note: Participation in COVID-19 treatment trials is permitted in case of hospitalization due to COVID-19, after confirmation of positive PCR. The study team should be informed as soon as possible. Participants with COVID-19 not hospitalized with positive PCR results for COVID-19 may be medicated according to standard clinical practice.
• Participation in SARS-CoV-2 serological research where participants are informed of their serological status during the course of the study;
• Planned receipt of any vaccine (authorized or investigational), within 30 days before and after vaccination;
• Prior receipt of an investigational vaccine or authorized with the possibility of impacting the interpretation of the study data (for example, vaccines vectorized by Adenovirus, any vaccines against coronavirus);
• Administration of immunoglobulins and/or any blood products in the three months prior to the planned administration of the candidate vaccine;
• Any confirmed or suspected immunosuppressive or immunodeficiency state; asplenia; severe recurrent infections and chronic use (more than 14 days) of immunosuppressive medication in the last 6 months, except for topical steroids or short-term oral steroids (cycle lasting ≤14 days);
• History of allergic disease or reactions possibly exacerbated by any component of ChAdOx1 nCoV-19 or MenACWY or paracetamol;
• Any history of angioedema;
• Any history of anaphylaxis;
• Pregnancy, lactation or willingness/intention to become pregnant during the study;
• Current diagnosis or treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ);
• History of severe psychiatric illness that possibly affects your participation in the study;
• Hemorrhagic disorder (for example, factor deficiency, coagulopathy or platelet disorder), or a previous history of significant bleeding or bruising after IM injections or venipuncture;
• Current suspected or known dependence on alcohol or drugs;
• Severe and/or uncontrolled cardiovascular diseases, respiratory diseases, gastrointestinal diseases, liver disease, kidney disease, endocrine disorder, and neurological disease (mild/moderate well-controlled comorbidities are allowed);
• History of COVID-19 confirmed by laboratory;
• Seropositive for antibodies to SARS-CoV-2 before recruitment; This exclusion criteria does not apply to participants enrolled from version 4.0 of the protocol onwards
• Continued use of anticoagulants, such as coumarins and related anticoagulants (for example, warfarin) or new oral anticoagulants (for example, apixaban, rivaroxaban, dabigatran and edoxaban);
• Any other significant illness, disorder or finding that may significantly increase the risk for the participant, affect his/her ability to participate in the study or impair the interpretation of the study data.

Re-vaccination exclusion criteria (two-dose groups only)

• Anaphylactic reaction following administration of vaccine
• Pregnancy

Study Plan

How is the study designed?

Design Details

• Primary Purpose: PREVENTION
• Allocation: RANDOMIZED
• Interventional Model: SEQUENTIAL
• Masking: SINGLE

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Group 1a: single dose ChAdOx & paracetamol; Participants will receive a single standard dose of ChAdOx1 nCOV19 vaccine plus paracetamol	Biological: ChAdOx1 nCoV-19 single dose + paracetamol; Single dose of ChAdOx1nCOV19 vaccine, 5x10^10 vp + paracetamol
ACTIVE_COMPARATOR: Group 1b: single dose MenACWY & paracetamol; Participants will receive a single dose of MenACWY plus paracetamol	Biological: MenACWY single dose + paracetamol; Single dose of MenACWY + paracetamol
EXPERIMENTAL: Group 1c: two dose ChAdOx & paracetamol; Participants will receive two standard doses of ChAdOx1 nCoV-19 vaccine, 4-12 weeks apart, plus paracetamol	Biological: ChAdOx1 nCoV-19 two dose + paracetamol; Two dose of ChAdOx1 nCoV-19 vaccine, 5x10^10vp (prime) and 0.5mL boost (3.5 - 6.5 × 10^10 vp), 4-12 weeks apart + paracetamol
ACTIVE_COMPARATOR: Group 1d: two dose MenACWy/saline & paracetamol; Participants will receive MenACWY prime, and Saline Placebo boost (0.5mL) plus paracetamol	Biological: MenACWY prime & saline placebo boost + paracetamol; MenACWY prime, and Saline Placebo boost (0.5mL) + paracetamol

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate the efficacy of ChAdOx1 nCoV-19 vaccine against COVID-19 disease confirmed with PCR	COVID-19 virologically confirmed symptomatic cases (PCR positive).	12 months post final vaccination

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate the safety, tolerability and reactogenicity profile of ChAdOx1 nCoV-19 candidate vaccine: occurrence of signs and symptoms of local and systemic reactogenicity requested during 7 days after vaccination	Occurrence of signs and symptoms of local and systemic reactogenicity requested during 7 days after vaccination (in a subset of 200 participants)	7 days post vaccination
Evaluate the safety, tolerability and reactogenicity profile of ChAdOx1 nCoV-19 candidate vaccine: occurrence of serious adverse events	Occurrence of serious adverse events	12 months post final vaccination
Evaluate the safety, tolerability and reactogenicity profile of ChAdOx1 nCoV-19 candidate vaccine: occurrence of episodes; intensified disease	Occurrence of episodes; intensified disease	12 months post final vaccination
Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: hospitalization for COVID-19 disease confirmed by PCR	Hospitalization for COVID-19 disease confirmed by PCR	12 months post final vaccination
Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: COVID-19 serious disease confirmed by PCR	COVID-19 serious disease confirmed by PCR	12 months post final vaccination
Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: death associated with COVID-19 disease	Death associated with COVID-19 disease	6 months
Evaluate the efficacy of ChAdOx1 nCoV-19 candidate vaccine against severe and non-severe COVID-19 disease: antibodies against SARS-CoV-2 non-Spike protein (serum efficacy rates)	Antibodies against SARS-CoV-2 non-Spike protein (serum efficacy rates).	12 months post final vaccination
Evaluate the humoral immunogenicity of ChAdOx1 nCoV-19: antibodies against the SARS-CoV-2 spike protein (serum conversion rates)	Antibodies against the SARS-CoV-2 spike protein (serum conversion rates)	12 months post final vaccination
Evaluate the humoral immunogenicity of ChAdOx1 nCoV-19: virus neutralizing antibodies (NAb) against live and/or pseudotyped SARS-CoV-2 virus	Virus neutralizing antibodies (NAb) against live and/or pseudotyped SARS-CoV-2 virus	12 months post final vaccination
Assess the cellular immunogenicity of ChAdOx1 nCoV-19 candidate vaccine	Interferon-gamma (IFN-γ) enzyme-linked immunospot (ELISpot) responses to SARS-CoV-2 spike protein	12 months post final vaccination

Collaborators and Investigators

• Sponsor: University of Oxford

Study record dates

Study Major Dates

• Study Start (ACTUAL): June 2, 2020
• Primary Completion (ANTICIPATED): September 1, 2021
• Study Completion (ANTICIPATED): September 1, 2021

Study Registration Dates

• First Submitted: September 1, 2020
• First Submitted That Met QC Criteria: September 1, 2020
• First Posted (ACTUAL): September 2, 2020

Study Record Updates

• Last Update Posted (ACTUAL): November 27, 2020
• Last Update Submitted That Met QC Criteria: November 23, 2020
• Last Verified: September 1, 2020

More Information

Terms related to this study

• Keywords: vaccine; Covid-19; sars-cov-2; ChAdOx1 nCov19
• Additional Relevant MeSH Terms: Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Coronavirus Infections; Physiological Effects of Drugs; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Analgesics, Non-Narcotic; Antipyretics; Acetaminophen
• Other Study ID Numbers: COV003

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No